PepGen Inc. (PEPG): Total Assets
$173.91M
As of 2025-12-31
$141.40M
As of 2026-06-30
-7.2%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $173.91M | +15.3% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $150.88M | +5.5% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $143.05M | -34.2% | 2025-02-24, Balance as of period end |
| 2022-12-31 | $217.44M | +51.4% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $143.64M | n/a | 2023-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| PepGen Inc. (PEPG) | 2025-12-31 | $173.91M | +15.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $169.01M | -4.7% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $168.19M | +7.9% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $167.74M | -22.8% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $182.62M | +83.4% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $164.18M | n/m |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $184.69M | +4.0% |
Compare PEPG, GOSS, ELDN, CRBP side by side · Screen every company in Pharmaceutical Preparations ↗